Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature

Snast, Igor; Atzmony, Lihi; Braun, Marius; Hodak, Emmilia; Pavlovsky, Lev

doi:10.1016/j.jaad.2017.01.037

Cited by 87 publications

(75 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Snast et al . published a systematic review of the published work including 49 studies about the risk of hepatitis B and C virus (HBV/HCV) reactivation in psoriatic patients receiving biologics.…”

Section: Safety Concerns Common In Biologicsmentioning

confidence: 99%

“…The lower risk of HBV reactivation in psoriatic patients may reflect the less frequent use of concomitant immunosuppressants than in rheumatic patients . Patients with chronic HBV infection, characterized by antigen positivity regardless of the status of other serological markers, are at greatest risk for HBV reactivation . In immunosuppressed patients with chronic HBV infection, oral anti‐HBV agents have proven to be effective in reducing acute exacerbation and preventing fatal complications .…”

Section: Safety Concerns Common In Biologicsmentioning

confidence: 99%

See 1 more Smart Citation

Safety of biologics in psoriasis

Kamata

Tada

2017

The Journal of Dermatology

109

View full text Add to dashboard Cite

The advent of biologics brought a paradigm shift in ways to treat psoriatic patients because they have dramatic efficacy. At the same time, safety concerns about biologics have been raised. In this paper, we focus on the safety profile of biologics for psoriasis. As of 2017, six biologics are available in Japan. Two tumor necrosis factor-a inhibitors; infliximab and adalimumab, one anti-interleukin (IL)-12/23p40 antibody; ustekinumab, and IL-17 inhibitors; secukinumab, ixekizumab and brodalumab. Secukinumab and ixekizumab are anti-IL-17A antibodies. Brodalumab is an anti-IL17RA antibody. In this review, we pick up topics which have drawn attention regarding the safety of biologics and discuss them with recent published work.

show abstract

Section: Safety Concerns Common In Biologicsmentioning

confidence: 99%

Section: Safety Concerns Common In Biologicsmentioning

confidence: 99%

Safety of biologics in psoriasis

Kamata

Tada

2017

The Journal of Dermatology

109

View full text Add to dashboard Cite

show abstract

“…However, the aforementioned studies included not only patients with psoriasis, but also patients with other rheumatic and digestive diseases (22). A more recent review by Snast et al (17) included 40 patients with psoriasis with chronic HBV infection and found that virus reactivation was documented in 8 (20%) patients on biologic therapy. Our previous study showed that 2 of 7 (29%) patients, not receiving antiviral prophylaxis, exhibited HBV reactivation during treatment with IL-12/23 p40 monoclonal antibody ustekinumab (6).…”

Section: Discussionmentioning

confidence: 99%

“…However, only one case report (37) and 3 patients with coexisting HBV infection undergoing secukinumab therapy were included in a recent study (17). None of the patients experienced hepatitis or virus reactivation.…”

Section: Discussionmentioning

confidence: 99%

“…Outcome HBV virological reactivation was defined as a 10-fold increase in the HBV-DNA load, compared with the baseline value or a switch from the "undetectable" to the "detectable" status, and/or hepatitis B e antigen (HBeAg) seroconversion from negative to positive after secukinumab therapy (6,16,17). Hepatitis was defined as a ≥ 3-fold increase in ALT level that exceeded the upper limit of the normal value or an absolute increase in ALT level to > 100 IU/l (18).…”

Section: Study Populationmentioning

confidence: 99%

See 1 more Smart Citation

Safety Proﬁle of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study

Chiu¹,

Hui²,

Huang³

et al. 2018

Acta Derm Venerol

View full text Add to dashboard Cite

SIGNIFICANCEThis study showed that biologic agents alter the competence of the host immune-surveillance system to combat hepatitis virus infections and hepatitis B virus (HBV) or hepatitis C virus (HCV). Reactivation can occur in patients with psoriasis with concurrent HBV or HCV treated with secukinumab, an anti-interleukin 17 agent. The risk of virus reactivation varied in patients with psoriasis with different virological profiles. It is advisable to monitor the viral load/ serum transaminase level and consider antiviral prophylaxis for all hepatitis B surface antigen-positive patients with psoriasis who are being treated with secukinumab.

show abstract